Search clinical trials for: Molidustat(BAY85-3934)

Total 508 results

Bayer

Recruiting

A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia

Renal Anemia

Japan
Bayer

Completed

Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)

Kidney Diseases

Germany
Bayer

Completed

To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects

Renal Insufficiency, Chronic

Germany
Bayer

Completed

Maintenance Treatment of Renal Anemia in Dialysis Subjects (MIYABI HD-M)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects (MIYABI ND-M)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects (MIYABI PD)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects (MIYABI HD-C)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE5)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Bayer

Completed

A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects (MIYABI ND-C)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

Long-term Pre-dialysis Extension in Europe and Asia Pacific (DIALOGUE 3)

Renal Insufficiency, Chronic | Anemia

United Kingdom, France, Spain, Japan, Hungary, Korea, Republic of, Israel, Italy, Bulgaria, Australia, Germany, Poland, Romania, Turkey
Bayer

Completed

Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects

Anemia

Germany
Bayer

Completed

Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)

Anemia

Germany, United Kingdom
Bayer

Completed

15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific) (DIALOGUE 1)

Renal Insufficiency, Chronic | Anemia

Japan, Korea, Republic of, United Kingdom, Hungary, Israel, Spain, Bulgaria, Australia, Germany, Italy, Poland, Romania, Turkey, France
Bayer

Completed

Age and Gender Effects on the Pharmacokinetics of BAY85-3934

Anemia

United States
Bayer

Completed

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE4)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Bayer

Completed

Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934 (DIALOGUE 2)

Renal Insufficiency, Chronic | Anemia

Japan, Hungary, Spain, United Kingdom, Israel, Bulgaria, Australia, France, Germany, Italy, Korea, Republic of, Poland, Romania, Turkey
Palatin Technologies, Inc

Withdrawn

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

Asthma

United States
Palatin Technologies, Inc

Recruiting

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

Heart Failure With Preserved Ejection Fraction

United States
Bayer

Completed

Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis

Bronchiectasis

Italy, Spain, Germany, United Kingdom, France
Bayer

Completed

Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients

Neoplasm

Germany
Sunovion

Completed

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Bayer

Completed

Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers

Alzheimer's Disease | Positron-Emission Tomography

Netherlands, Sweden
National Institute of Allergy and Infectious Diseases...
Schering-Plough

Completed

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

HIV Infections | Meningitis, Cryptococcal

United States
Vir Biotechnology, Inc.

Recruiting

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Hepatitis D, Chronic

New Zealand, United Kingdom, Moldova, Republic of, Romania, Bulgaria, Italy, Germany, France, Netherlands
Valentis

Completed

Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease

Peripheral Vascular Disease

United States
Bayer

Completed

Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers

Diagnostic Imaging

Finland, Netherlands
University Health Network, Toronto

Recruiting

Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]

Hepatitis B, Chronic

Canada
Chong Kun Dang Pharmaceutical

Completed

A Study to Investigate the PK and Safety of CKD-393

Type II Diabetes

Korea, Republic of
Vir Biotechnology, Inc.

Recruiting

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Cirrhosis | Hepatic Impairment

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393

Type II Diabetes Mellitus

Korea, Republic of
Bayer

Completed

Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (Phoenix II)

Dermatitis, Atopic

Germany
Bayer

Completed

Gadobutrol Magnevist-controlled Body Study

Magnetic Resonance Imaging

China, Korea, Republic of, Japan
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Vascular Diseases

China
Bayer

Completed

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Contrast Enhanced X-ray Based Examination

Germany
Bayer

Completed

Japanese BAY80-6946 Monotherapy Phase I Study

Neoplasms

Japan
Bayer

Terminated

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies

Neoplasms

Germany, United Kingdom, Norway
Life Molecular Imaging SA

Completed

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Diagnostic Imaging

Singapore
Bayer

Completed

Japanese BAY86-9766 Monotherapy Phase I Study

Neoplasms

Japan
Merck Sharp & Dohme LLC

Completed

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Prostate Cancer | Bladder Carcinoma | Colon Carcinoma | Non-Small Cell Lung Carcinoma | Upper GI Tract Carcinoma
Bayer

Completed

Copanlisib Pharmacodynamic Study

Non Hodgkin Lymphoma

Belgium, France, United Kingdom
Bayer

Completed

Copanlisib Mass Balance Study

Healthy Volunteers

Netherlands
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Type 2 Diabetes

Korea, Republic of
Bayer

Completed

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Lymphoma Non-Hodgkin

Japan
Bayer

Active, not recruiting

A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Taiwan
Bayer
Titan Pharmaceuticals

Terminated

Pilot Study of Safety and Efficacy of Spheramine

Parkinson''s Disease

United States
Vir Biotechnology, Inc.

Completed

Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Germany, Hong Kong, Korea, Republic of, New Zealand, Romania, Singapore, United Kingdom
Bayer

Completed

Study of Copanlisib in Hepatic or Renal Impairment

Hepatic Insufficiency, Renal Insufficiency

Germany, Romania
Bayer

Completed

Safety of Gadovist in Renally Impaired Patients (GRIP)

Fibrosis | Renal Impairment

Italy, Spain, Korea, Republic of, Germany, Canada, France, Austria, Thailand, Australia, Switzerland
Bayer
Titan Pharmaceuticals

Terminated

STEPS Trial - Spheramine Safety and Efficacy Study

Parkinson Disease

Spain, United States, Germany
Bayer

Terminated

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE 2)

Acute Heart Failure

Belgium, France, Argentina, United States, Austria, Mexico, Germany, Philippines, Ireland

3

Subscribe